Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.

Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA.

Ann Oncol. 2016 Nov;27(11):2124-2130.

PMID:
27793850
2.

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.

Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS.

Br J Pharmacol. 2006 Aug;148(8):1116-23. Epub 2006 Jul 10. Erratum in: Br J Pharmacol. 2007 Jan;150(2):248.

3.

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK.

Neuro Oncol. 2006 Jan;8(1):67-78.

4.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A.

J Clin Oncol. 2005 Apr 10;23(11):2544-55. Epub 2005 Mar 7.

PMID:
15753462
5.

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.

Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, Hidalgo M.

Clin Cancer Res. 2004 Oct 1;10(19):6522-7.

6.
7.

Targeting death receptors in cancer with Apo2L/TRAIL.

Kelley SK, Ashkenazi A.

Curr Opin Pharmacol. 2004 Aug;4(4):333-9. Review.

PMID:
15251125
8.
9.
10.

Mobilization of vitamin A stores in rats after administration of 2,3, 7,8-tetrachlorodibenzo-p-dioxin: a kinetic analysis.

Kelley SK, Nilsson CB, Green MH, Green JB, Håkansson H.

Toxicol Sci. 2000 Jun;55(2):478-84.

PMID:
10828281
11.

Plasma retinol is a major determinant of vitamin A utilization in rats.

Kelley SK, Green MH.

J Nutr. 1998 Oct;128(10):1767-73.

PMID:
9772148
12.

Use of model-based compartmental analysis to study effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on vitamin A kinetics in rats.

Kelley SK, Nilsson CB, Green MH, Green JB, Håkansson H.

Toxicol Sci. 1998 Jul;44(1):1-13.

PMID:
9720135
13.

Plasma thyroid hormone kinetics are altered in iron-deficient rats.

Beard JL, Brigham DE, Kelley SK, Green MH.

J Nutr. 1998 Aug;128(8):1401-8.

PMID:
9687562
14.

A survey of human resources in managed care organizations.

Kelley SK, Trautlein JJ.

Physician Exec. 1992 Nov-Dec;18(6):49-51.

PMID:
10122614

Supplemental Content

Loading ...
Support Center